CoLucid Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference
29 November 2016 - 5:59AM
CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical
company that is developing lasmiditan oral tablets for the acute
treatment of migraine in adults, with or without aura, announced
today it will provide a corporate overview at the 28th Annual Piper
Jaffray Healthcare Conference, being held on November 29-30 in New
York City.
28th Annual Piper Jaffray
Healthcare Conference |
Date: |
|
Wednesday, November 30 |
Time: |
|
1:00 pm Eastern Time |
Location: |
|
The Lotte New York Palace Hotel, Holmes I
Room |
Webcast: |
|
http://edge.media-server.com/m/p/cfdngzft |
About CoLucid Pharmaceuticals, Inc.CoLucid is
developing lasmiditan oral tablets for the acute treatment of
migraine headaches in adults and intravenous lasmiditan for the
acute treatment of headache pain associated with migraine in adults
in emergency room and other urgent care settings.
CONTACT
Thomas Mathers
Chief Executive Officer
CoLucid Pharmaceuticals, Inc.
(857) 285-6494
Hans Vitzthum
Managing Director
LifeSci Advisors, LLC.
(212) 915-2568
COLUCID PHARMACEUTICALS, INC. (NASDAQ:CLCD)
Historical Stock Chart
From Apr 2024 to May 2024
COLUCID PHARMACEUTICALS, INC. (NASDAQ:CLCD)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Colucid Pharmaceuticals, Inc. (NASDAQ): 0 recent articles
More News Articles